E. Alejandro Sweet-Cordero, MD
Functional Analysis of Novel Oncogenic Kras Effector Pathways
Dr. E. Alejandro Sweet-Cordero will be investigating the role of K-Ras in lung cancer. Mutations in the K-Ras gene are associated with lung cancer but the mechanism by which they cause the disease is poorly understood. Elucidating the exact biochemical pathway governed by this gene may provide specific molecular targets for new drug therapies.
Dr. Sweet-Cordero identified a novel connection between oncogenic K-Ras and the Wilm’s tumor suppressor (Wt1). Dr. Sweet-Cordero is currently carrying out further studies to understand the mechanistic basis of this finding and to extend the observations to clinical samples of NSCLC.
Dr. Sweet-Cordero received over $500,000 from the National Cancer Institute to continue his work on “Identification of Novel KRas Effector Pathways in Lung Cancer.”